Silverfin false false 31/12/2024 01/01/2024 31/12/2024 Justin David Christian Barnes 15/05/2024 19/10/2023 Dr Glenn Crocker 14/03/2024 Dr Joseph Henry Hedley 02/03/2021 Martlet Capital Directors Limited 30/09/2024 Colin Mitchell 31/01/2024 28/07/2021 Dr Alisa Molotova 30/09/2024 07/03/2023 Dr Andrew Robert Pike 06/06/2012 Sandy Blackadder Primrose 07/08/2024 07/03/2023 Carl Andrew Sterritt 09/09/2024 Gemma Elizabeth Olivia Sturt 14/03/2024 07/03/2023 Dr Eimer Mary Tuite 06/06/2012 Christopher Mark Wheatcroft 07/03/2023 16 July 2025 The principal activity of the Company was that of Synthetic DNA production. 08093593 2024-12-31 08093593 bus:Director1 2024-12-31 08093593 bus:Director2 2024-12-31 08093593 bus:Director3 2024-12-31 08093593 bus:Director4 2024-12-31 08093593 bus:Director5 2024-12-31 08093593 bus:Director6 2024-12-31 08093593 bus:Director7 2024-12-31 08093593 bus:Director8 2024-12-31 08093593 bus:Director9 2024-12-31 08093593 bus:Director10 2024-12-31 08093593 bus:Director11 2024-12-31 08093593 bus:Director12 2024-12-31 08093593 2023-12-31 08093593 core:CurrentFinancialInstruments 2024-12-31 08093593 core:CurrentFinancialInstruments 2023-12-31 08093593 core:Non-currentFinancialInstruments 2024-12-31 08093593 core:Non-currentFinancialInstruments 2023-12-31 08093593 core:ShareCapital 2024-12-31 08093593 core:ShareCapital 2023-12-31 08093593 core:SharePremium 2024-12-31 08093593 core:SharePremium 2023-12-31 08093593 core:RetainedEarningsAccumulatedLosses 2024-12-31 08093593 core:RetainedEarningsAccumulatedLosses 2023-12-31 08093593 core:OtherResidualIntangibleAssets 2023-12-31 08093593 core:OtherResidualIntangibleAssets 2024-12-31 08093593 core:OtherPropertyPlantEquipment 2023-12-31 08093593 core:OtherPropertyPlantEquipment 2024-12-31 08093593 2024-01-01 2024-12-31 08093593 bus:FilletedAccounts 2024-01-01 2024-12-31 08093593 bus:SmallEntities 2024-01-01 2024-12-31 08093593 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 08093593 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 08093593 bus:Director1 2024-01-01 2024-12-31 08093593 bus:Director2 2024-01-01 2024-12-31 08093593 bus:Director3 2024-01-01 2024-12-31 08093593 bus:Director4 2024-01-01 2024-12-31 08093593 bus:Director5 2024-01-01 2024-12-31 08093593 bus:Director6 2024-01-01 2024-12-31 08093593 bus:Director7 2024-01-01 2024-12-31 08093593 bus:Director8 2024-01-01 2024-12-31 08093593 bus:Director9 2024-01-01 2024-12-31 08093593 bus:Director10 2024-01-01 2024-12-31 08093593 bus:Director11 2024-01-01 2024-12-31 08093593 bus:Director12 2024-01-01 2024-12-31 08093593 core:PatentsTrademarksLicencesConcessionsSimilar 2024-01-01 2024-12-31 08093593 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 08093593 2023-01-01 2023-12-31 08093593 core:OtherResidualIntangibleAssets 2024-01-01 2024-12-31 08093593 1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Company No: 08093593 (England and Wales)

NUNABIO LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

NUNABIO LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

NUNABIO LIMITED

COMPANY INFORMATION

For the financial year ended 31 December 2024
NUNABIO LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2024
DIRECTORS Justin David Christian Barnes (Resigned 15 May 2024)
Dr Glenn Crocker (Appointed 14 March 2024)
Dr Joseph Henry Hedley
Martlet Capital Directors Limited (Appointed 30 September 2024)
Colin Mitchell (Resigned 31 January 2024)
Dr Alisa Molotova (Resigned 30 September 2024)
Dr Andrew Robert Pike
Sandy Blackadder Primrose (Resigned 07 August 2024)
Carl Andrew Sterritt (Appointed 09 September 2024)
Gemma Elizabeth Olivia Sturt (Resigned 14 March 2024)
Dr Eimer Mary Tuite
Christopher Mark Wheatcroft
REGISTERED OFFICE Time Central
32 Gallowgate
Newcastle Upon Tyne
NE1 4BF
United Kingdom
COMPANY NUMBER 08093593 (England and Wales)
ACCOUNTANT S&W Partners Newcastle Limited
17 Queens Lane
Newcastle
NE1 1RN
NUNABIO LIMITED

BALANCE SHEET

As at 31 December 2024
NUNABIO LIMITED

BALANCE SHEET (continued)

As at 31 December 2024
Note 2024 2023
£ £
Fixed assets
Intangible assets 3 83,823 20,769
Tangible assets 4 972,172 378,110
1,055,995 398,879
Current assets
Debtors 5 418,472 275,608
Cash at bank and in hand 481,981 1,539,117
900,453 1,814,725
Creditors: amounts falling due within one year 6 ( 876,288) ( 30,315)
Net current assets 24,165 1,784,410
Total assets less current liabilities 1,080,160 2,183,289
Creditors: amounts falling due after more than one year 7 ( 1,483,197) ( 1,100,010)
Net (liabilities)/assets ( 403,037) 1,083,279
Capital and reserves
Called-up share capital 6,514 6,514
Share premium account 2,095,853 2,095,853
Profit and loss account ( 2,505,404 ) ( 1,019,088 )
Total shareholders' (deficit)/funds ( 403,037) 1,083,279

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of NunaBio Limited (registered number: 08093593) were approved and authorised for issue by the Board of Directors on 16 July 2025. They were signed on its behalf by:

Carl Andrew Sterritt
Director
NUNABIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
NUNABIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

NunaBio Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Time Central, 32 Gallowgate, Newcastle Upon Tyne, NE1 4BF, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with ‘The Financial Reporting Standard applicable in the UK and the Republic of Ireland’ issued by the Financial Reporting Council, including Section 1A of Financial Reporting Standard 102 (FRS102), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The functional currency of NunaBio Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise on monetary items.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the sale of goods is recognised when the goods are physically delivered to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on enacted or substantively enacted tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment.

Other intangible assets not amortised
Trademarks, patents and licences

Separately acquired patents and trademarks are included at cost. Provision is made for any impairment.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. 20 - 33 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 17 12

3. Intangible assets

Other intangible assets Total
£ £
Cost
At 01 January 2024 20,769 20,769
Additions 63,054 63,054
At 31 December 2024 83,823 83,823
Accumulated amortisation
At 01 January 2024 0 0
At 31 December 2024 0 0
Net book value
At 31 December 2024 83,823 83,823
At 31 December 2023 20,769 20,769

4. Tangible assets

Plant and machinery etc. Total
£ £
Cost
At 01 January 2024 427,514 427,514
Additions 775,836 775,836
At 31 December 2024 1,203,350 1,203,350
Accumulated depreciation
At 01 January 2024 49,404 49,404
Charge for the financial year 181,774 181,774
At 31 December 2024 231,178 231,178
Net book value
At 31 December 2024 972,172 972,172
At 31 December 2023 378,110 378,110

5. Debtors

2024 2023
£ £
Trade debtors 61,062 27,260
Corporation tax 105,012 0
Other debtors 252,398 248,348
418,472 275,608

6. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 136,904 62,671
Other taxation and social security 20,354 14,580
Obligations under finance leases and hire purchase contracts 141,509 0
Other creditors 577,521 ( 46,936)
876,288 30,315

7. Creditors: amounts falling due after more than one year

2024 2023
£ £
Obligations under finance leases and hire purchase contracts 183,192 0
Other creditors 1,300,005 1,100,010
1,483,197 1,100,010

8. Events after the Balance Sheet date

On 3 March 2025, the company allotted 709,196 shares with a nominal value of £7,091.96.